Every 424B that Adagio Medical Holdings, Inc (ADGM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ADGM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADGM filings page.
Adagio Medical Holdings, Inc. registers up to 67,963,695 shares of Common Stock for resale by the selling stockholders named in the prospectus supplement. The registration encompasses multiple components including PIPE Shares, Pre-Funded Warrant Shares, PIPE Warrant Shares, Convertible Note Shares and various sponsor‑ and option‑related shares.
The supplement incorporates the company’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 and states a last reported sales price of $1.24 per share on March 26, 2026. Shares outstanding were 22,210,459 as of March 23, 2026.
Adagio Medical Holdings, Inc. registers up to 31,818,652 shares of Common Stock for resale by selling stockholders. This prospectus supplement, dated March 27, 2026, covers 73,333 Registration Delay Shares, up to 31,145,319 Convertible Note Shares issuable upon conversion of 13% senior secured convertible notes (conversion price $10.00 per share, subject to adjustment), and up to 600,000 Warrant Shares issuable upon exercise of warrants with a $24.00 exercise price.
Shares outstanding were 22,210,459 as of March 23, 2026. The prospectus supplement incorporates the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and states these are offered for resale by the selling stockholders.
Adagio Medical Holdings, Inc. filed a prospectus supplement covering the potential resale of up to 67,963,695 shares of common stock by existing security holders. These shares include PIPE shares and pre-funded warrant shares, common stock issuable upon exercise of PIPE and convert warrants, and up to 46,717,980 shares issuable upon conversion of 13% senior secured convertible notes, along with various sponsor, business combination and option shares.
The supplement attaches a Current Report detailing the company’s 2025 annual stockholder meeting. Of 21,179,637 shares outstanding on the record date, 13,862,436 shares (65.45%) were represented. Stockholders elected directors Todd Usen and James L. Cox, M.D., and ratified WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2025. Adagio’s common stock trades on Nasdaq under the symbol ADGM, and last traded at $1.18 per share on December 16, 2025.
Adagio Medical Holdings, Inc. has filed a prospectus supplement covering the potential resale of up to 31,818,652 shares of common stock by selling stockholders. This total includes 73,333 Registration Delay Shares already issued, up to 31,145,319 shares issuable upon conversion of 13% senior secured convertible notes at $10.00 per share, and up to 600,000 shares issuable upon exercise of warrants at $24.00 per share.
The supplement also includes the company’s latest stockholder meeting report. Shares outstanding were 21,179,637 as of the record date, with 65.45% represented at the 2025 annual meeting. Stockholders elected two directors to terms ending in 2028 and ratified WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2025.
Adagio Medical Holdings, Inc. is registering up to 27,831,335 shares of common stock for resale by existing investors, including 5,798,072 outstanding shares, 3,994,434 shares issuable upon exercise of pre-funded warrants, and 18,038,829 shares issuable upon exercise of milestone warrants. These securities were issued in an October 2025 private placement that provided approximately $19 million in gross proceeds, with up to about $31 million more potentially available if all milestone warrants are exercised for cash at $1.71 per share.
The company will not receive any proceeds from resales of these shares, only from any future cash exercises of the pre-funded or milestone warrants. Adagio develops catheter-based ultra-low temperature cryoablation technology targeting ventricular tachycardia, a life‑threatening heart rhythm disorder. As of October 31, 2025, it had 21,179,637 shares of common stock outstanding. Adagio is an “emerging growth company” and “smaller reporting company,” allowing it to use scaled disclosure and certain reporting exemptions.
Adagio Medical Holdings, Inc. has filed a prospectus supplement covering the potential resale of up to 31,818,652 shares of common stock by selling stockholders. This total includes 73,333 Registration Delay Shares already issued, up to 31,145,319 shares issuable upon conversion of 13% senior secured convertible notes with a $10.00 per share conversion price, and up to 600,000 shares issuable upon exercise of warrants with a $24.00 per share exercise price. These securities were issued or are issuable under prior financing agreements, and this document updates the existing prospectus with a recent Current Report on Form 8-K. The company’s common stock trades on Nasdaq under the symbol ADGM, with a last reported price of $0.8779 per share on December 11, 2025.
Adagio Medical Holdings, Inc. filed a prospectus supplement covering the resale of up to 67,963,695 shares of its common stock by existing holders. The shares include previously issued stock, as well as shares issuable upon exercise of pre-funded warrants and other warrants, and upon conversion of 13% senior secured convertible notes, all tied to prior financing and business combination agreements. The supplement incorporates a recent Current Report on Form 8-K into the existing prospectus and must be read together with that document. Adagio’s common stock trades on the Nasdaq Capital Market under the symbol ADGM, and the last reported sales price on December 11, 2025 was $0.8779 per share. The company is classified as an emerging growth company and highlights that investing in its securities involves a high degree of risk.
Adagio Medical Holdings (ADGM) filed a prospectus supplement for the resale of up to 31,818,652 shares of common stock by selling stockholders. This covers 73,333 Registration Delay Shares, up to 31,145,319 shares issuable upon conversion of 13% senior secured convertible notes at $10.00 per share, and up to 600,000 shares issuable upon exercise of warrants at $24.00 per share. The supplement attaches the company’s latest Quarterly Report on Form 10‑Q.
In the quarter ended September 30, 2025, Adagio reported a net loss of $10.1 million, cash and cash equivalents of $4.7 million, and stockholders’ deficit of $1.3 million. The company announced a private placement in October 2025 for approximately $19 million in aggregate gross proceeds, and management states available cash, including those proceeds, is sufficient for at least 12 months from the report date. Shares outstanding were 21,179,637 as of November 10, 2025. ADGM last closed at $0.8724 on November 11, 2025.
Adagio Medical Holdings, Inc. (ADGM) filed a prospectus supplement tied to its Form S-1 covering the potential resale of up to 67,963,695 shares of common stock by selling stockholders. The registration includes up to 12,146,988 shares of common stock, up to 9,098,727 shares issuable upon exercise of warrants (including pre-funded, PIPE, and convert warrants), and up to 46,717,980 shares issuable upon conversion of 13% senior secured convertible notes.
The supplement also attaches a Current Report announcing the 2025 Annual Meeting on December 15, 2025, with a record date of October 31, 2025. Stockholder proposals and director nominations must be received by November 3, 2025 under Rule 14a-8, the company’s bylaws, and Rule 14a-19, as applicable. ADGM is listed on Nasdaq; the last reported price was $1.31 per share on October 23, 2025.
Adagio Medical Holdings (ADGM) filed a prospectus supplement for a resale offering covering up to 31,818,652 shares of common stock by selling stockholders. This includes 73,333 Registration Delay Shares, up to 31,145,319 Convertible Note Shares issuable upon conversion of 13% senior secured convertible notes at a $10.00 conversion price (subject to adjustment), and up to 600,000 Warrant Shares issuable upon exercise of warrants with a $24.00 exercise price. The supplement incorporates an attached Current Report on Form 8‑K.
Separately, the company set its 2025 Annual Meeting for December 15, 2025, with a record date of October 31, 2025. Stockholder proposals and director nominations are due by November 3, 2025 under Rule 14a‑8, the bylaws, and Rule 14a‑19. ADGM is listed on Nasdaq; the last reported sales price was $1.31 per share on October 23, 2025.